196 Checkpoint blockade therapy for brain-metastatic non-small cell lung cancer: a comparative effectiveness analysis of national data

196 Checkpoint blockade therapy for brain-metastatic non-small cell lung cancer: a comparative effectiveness analysis of national data

Bibliographic Details
Main Author:	Nayan Lamba
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma
by: Hong Yuan, et al.
Published: (2021-03-01)

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
by: Janice M Mehnert, et al.
Published: (2020-07-01)

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
by: Feiyu Zhang, et al.
Published: (2021-05-01)

Immune-Checkpoint Blockade Therapy in Lymphoma
by: Ayumi Kuzume, et al.
Published: (2020-07-01)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
by: Sijia Ren, et al.
Published: (2021-06-01)

Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade
by: Linan Fang, et al.
Published: (2019-03-01)

Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients
by: Richard Carvajal, et al.
Published: (2020-06-01)

Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
by: Valerio Nardone, et al.
Published: (2021-06-01)

Acquired Resistance to Immune Checkpoint Blockade Therapies
by: Xianda Zhao, et al.
Published: (2020-05-01)

The role of neoantigen in immune checkpoint blockade therapy
by: Ming Yi, et al.
Published: (2018-11-01)

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
by: Niki Karachaliou, et al.
Published: (2018-01-01)

Correction: Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients
by: Lisa Zimmer, et al.
Published: (2021-01-01)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
by: Marcin Nicoś, et al.
Published: (2020-12-01)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
by: Na Zhang, et al.
Published: (2020-11-01)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
by: Hongru Shen, et al.
Published: (2020-12-01)

Photothermal therapies to improve immune checkpoint blockade for cancer
by: Preethi B. Balakrishnan, et al.
Published: (2020-12-01)

Combination immune checkpoint blockade as an effective therapy for mesothelioma
by: Vanessa S. Fear, et al.
Published: (2018-10-01)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
by: Florent Petitprez, et al.
Published: (2020-05-01)

Immune checkpoint blockade therapy for bladder cancer treatment
by: Jayoung Kim
Published: (2016-06-01)

Combination approaches with immune checkpoint blockade in cancer therapy
by: Maarten Swart, et al.
Published: (2016-11-01)

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
by: Chiara Cremolini, et al.
Published: (2021-03-01)

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
by: Pfirschke, Christina, et al.
Published: (2018)

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer
by: Qingzhu Jia, et al.
Published: (2020-05-01)

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients
by: Koichi Saruwatari, et al.
Published: (2019-01-01)

Immune Checkpoint Blockade – How Does It Work in Brain Metastases?
by: Mihaela Lorger, et al.
Published: (2019-11-01)

The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non–Small Cell Lung Cancer: A Meta-Analysis
by: Sihan Li, et al.
Published: (2021-06-01)

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
by: Meihua Wang, et al.
Published: (2019-02-01)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
by: Junichi Soh, et al.
Published: (2021-08-01)

Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response
by: Kripa Guram, et al.
Published: (2018-10-01)

Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer
by: Guangsheng Zhu, et al.
Published: (2021-03-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
by: Laura Boyero, et al.
Published: (2020-12-01)

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
by: Jeffrey C Thompson, et al.
Published: (2020-07-01)

Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade
by: Alexander Chi, et al.
Published: (2021-06-01)

Resistance to checkpoint blockade therapy through inactivation of antigen presentation
by: Moshe Sade-Feldman, et al.
Published: (2017-10-01)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
by: Hao Wang, et al.
Published: (2019-06-01)

Mechanisms of immunogenic cell death and immune checkpoint blockade therapy
by: Richard A. Lin, et al.
Published: (2021-06-01)

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
by: Pranjal Vaidya, et al.
Published: (2020-07-01)

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients
by: Cristina Maccalli, et al.
Published: (2017-07-01)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
by: Markus V. Heppt, et al.
Published: (2019-11-01)